 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...195196197198199200201202203204205...235236» |
- || New P3 trial: PROMENADE: Proactive Management of Endoperitoneal Spread in Colonic Cancer (clinicaltrials.gov) - Nov 28, 2016
P3, N=140, Not yet recruiting, Sponsor: University of Roma La Sapienza
- | NN1213 / Novo Nordisk
Trial completion, Metastases: Immediate Compared With Delayed Chemotherapy in Advanced Colorectal Cancer Without Signs or Symptoms of Disease (clinicaltrials.gov) - Nov 27, 2016
P3, N=67, Completed, Sponsor: NCIC Clinical Trials Group
Active, not recruiting --> Completed
- NN1213 / Novo Nordisk
Trial primary completion date, Surgery, Metastases: Radiation Therapy and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Patients With Rectal Cancer (clinicaltrials.gov) - Nov 23, 2016
P2, N=23, Active, not recruiting, Sponsor: Fox Chase Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Jul 2016 --> Jul 2001
- Enrollment open, Metastases: A Dose Escalation Trial of SBRT After Induction Chemotherapy for Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Nov 23, 2016
P1, N=34, Recruiting, Sponsor: University of Colorado, Denver
Trial primary completion date: Jul 2016 --> Jul 2001 Not yet recruiting --> Recruiting
- ||||| New P2 trial, Metastases: POLAF: Phase II Trial to Assess FOLFIRI+Aflibercept Efficacy in Patients With Oxaliplatin-pretreated Metastatic Colorectal Cancer With or Without ACE Polymorphisms (clinicaltrials.gov) - Nov 22, 2016
P2, N=100, Not yet recruiting, Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
- Trial initiation date, Trial primary completion date, Metastases: A Dose Escalation Trial of SBRT After Induction Chemotherapy for Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Nov 21, 2016
P1, N=34, Not yet recruiting, Sponsor: University of Colorado, Denver
Not yet recruiting --> Recruiting Initiation date: Oct 2016 --> Jan 2017 | Trial primary completion date: Aug 2018 --> Aug 2019
- Avastin (bevacizumab) / Roche
Biomarker, Enrollment change, Trial termination, Metastases: Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Nov 16, 2016
P2, N=14, Terminated, Sponsor: CR-CSSS Champlain-Charles-Le Moyne
Initiation date: Oct 2016 --> Jan 2017 | Trial primary completion date: Aug 2018 --> Aug 2019 N=52 --> 14 | Active, not recruiting --> Terminated; Drug (Aflibercept) no longuer available for the study
- | Tomudex (raltitrexed) / Pfizer, AstraZeneca
New P2 trial, Metastases: Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Versus no HIPEC in Locally Advanced Colorectal Cancer (APEC Study) (clinicaltrials.gov) - Nov 16, 2016
P2, N=147, Recruiting, Sponsor: Fudan University
- Trial primary completion date, Surgery: Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine") (clinicaltrials.gov) - Nov 15, 2016
P2, N=130, Recruiting, Sponsor: Medical College of Wisconsin
N=52 --> 14 | Active, not recruiting --> Terminated; Drug (Aflibercept) no longuer available for the study Trial primary completion date: Jun 2017 --> Jun 2018
- ||| 5-fluorouracil / Generic mfg., cisplatin / Generic mfg., docetaxel / Generic mfg.
Enrollment closed: Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Nov 10, 2016
P2, N=111, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Jun 2017 --> Jun 2018 Recruiting --> Active, not recruiting
- ||| ipatasertib (RG7440) / Roche
Enrollment closed, Combination therapy, Metastases: A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Nov 10, 2016
P2, N=153, Active, not recruiting, Sponsor: Genentech, Inc.
Recruiting --> Active, not recruiting Completed --> Active, not recruiting
- Avastin (bevacizumab) / Roche
Trial completion, Trial primary completion date, Combination therapy, Metastases: Preoperative Chemoradiotherapy Utilizing Intensity Modulated Radiation Therapy in Combination With Bevacizumab-FOLFOX (clinicaltrials.gov) - Nov 10, 2016
P1, N=15, Completed, Sponsor: National Taiwan University Hospital
Completed --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Dec 2014 --> Mar 2015
- oxaliplatin / Generic mfg.
Trial primary completion date: Effect of GM1 in Prevention of Oxaliplatin Induced Neurotoxicity in Stage II/III Colorectal Cancer (clinicaltrials.gov) - Nov 10, 2016
P3, N=188, Recruiting, Sponsor: Yuhong Li
Recruiting --> Completed | Trial primary completion date: Dec 2014 --> Mar 2015 Trial primary completion date: Aug 2016 --> Aug 2017
- |||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date: CheckMate 649: Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (clinicaltrials.gov) - Nov 9, 2016
P3, N=870, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Aug 2016 --> Aug 2017 Trial primary completion date: Mar 2019 --> Jul 2019
- leucovorin calcium / Generic mfg.
New trial: PK/PD Investigation of Calciumfolinat in Blood, Tumor and Adjacent Mucosa in Patient With Colon Cancer (clinicaltrials.gov) - Nov 8, 2016
P=N/A, N=30, Enrolling by invitation, Sponsor: Vastra Gotaland Region
- | New P2 trial: PANACHE01-PRODIGE48 Study: Neo-adjuvant FOLF(IRIN)OX for Resectable Pancreatic Adenocarcinoma (clinicaltrials.gov) - Nov 8, 2016
P2, N=160, Not yet recruiting, Sponsor: University Hospital, Rouen
- ||| Xpovio (selinexor) / Karyopharm
Enrollment open, Enrollment change, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker: NCI-2015-00693: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies (clinicaltrials.gov) - Nov 8, 2016
P1, N=470, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Mar 2019 --> Jul 2019 Active, not recruiting --> Recruiting | N=88 --> 470
- Cyramza (ramucirumab) / Eli Lilly
Trial completion, Metastases: A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer (clinicaltrials.gov) - Nov 7, 2016
P1b, N=9, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Recruiting | N=88 --> 470 Active, not recruiting --> Completed
- crenolanib (ARO-002) / AROG
Enrollment closed, Enrollment change, Combination therapy: Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies (clinicaltrials.gov) - Nov 4, 2016
P1, N=10, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=24 --> 10
- || monalizumab (IPH2201) / AstraZeneca, Innate, Imfinzi (durvalumab) / AstraZeneca
Enrollment change, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker, Metastases: A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors (clinicaltrials.gov) - Nov 4, 2016
P1, N=175, Recruiting, Sponsor: MedImmune LLC
Recruiting --> Active, not recruiting | N=24 --> 10 N=232 --> 175 | Trial primary completion date: Sep 2019 --> Jun 2019
- |||| Avastin (bevacizumab) / Roche
Biomarker, Trial completion, Metastases: ASCENT: A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer (clinicaltrials.gov) - Nov 2, 2016
P4, N=128, Completed, Sponsor: Hoffmann-La Roche
N=232 --> 175 | Trial primary completion date: Sep 2019 --> Jun 2019 Active, not recruiting --> Completed
- |||| ipatasertib (RG7440) / Roche
Trial completion, Combination therapy, Metastases: A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Nov 2, 2016
P2, N=154, Completed, Sponsor: Genentech, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | veliparib (ABT-888) / AbbVie, Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, PARP Biomarker, Metastases: NRG-GI002: Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer (clinicaltrials.gov) - Nov 1, 2016
P2, N=174, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || veliparib (ABT-888) / AbbVie
Trial primary completion date, Metastases: Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 31, 2016
P2, N=120, Active, not recruiting, Sponsor: AbbVie
Not yet recruiting --> Recruiting Trial primary completion date: May 2017 --> Jan 2017
- Erbitux (cetuximab) / Eli Lilly
New trial, Tumor cell, Metastases: Evaluation of CTCs Combined With Tumor Marker Detection of Efficacy of Chemotherapy in mCRC (clinicaltrials.gov) - Oct 31, 2016
P=N/A, N=100, Not yet recruiting, Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- || telisotuzumab (h224G11) / AbbVie
Trial primary completion date, Metastases: Study of ABT-700 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Oct 27, 2016
P1, N=124, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: May 2017 --> Jan 2017 Trial primary completion date: Oct 2016 --> Apr 2017
- ||| Avastin (bevacizumab) / Roche
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: CHARTA: Efficacy of FOLFOX+Bevacizumab in Combination With Irinotecan in the Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 26, 2016
P2, N=250, Active, not recruiting, Sponsor: Martin-Luther-Universit
Trial primary completion date: Oct 2016 --> Apr 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Sep 2016
- || Xpovio (selinexor) / Karyopharm
Enrollment closed, Enrollment change, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker: NCI-2015-00693: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies (clinicaltrials.gov) - Oct 26, 2016
P1, N=88, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Sep 2016 Recruiting --> Active, not recruiting | N=470 --> 88
- || Erbitux (cetuximab) / Eli Lilly
Biomarker, New P2/3 trial, Monotherapy, Metastases: Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC (clinicaltrials.gov) - Oct 25, 2016
P2/3, N=200, Not yet recruiting, Sponsor: Ruijin Hospital
- | New P2 trial, Metastases: Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (clinicaltrials.gov) - Oct 25, 2016
P2, N=100, Active, not recruiting, Sponsor: RenJi Hospital
- Keytruda (pembrolizumab) / Merck (MSD)
New P2 trial, PD(L)-1 Biomarker, IO biomarker: A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach (clinicaltrials.gov) - Oct 24, 2016
P2, N=40, Not yet recruiting, Sponsor: Weijing Sun, MD, FACP
- oxaliplatin / Generic mfg., irinotecan / Generic mfg.
Trial termination, Trial primary completion date: Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study (clinicaltrials.gov) - Oct 20, 2016
P2, N=1, Terminated, Sponsor: Case Comprehensive Cancer Center
Recruiting --> Active, not recruiting | N=470 --> 88 Active, not recruiting --> Terminated | Trial primary completion date: Sep 2016 --> Feb 2016; Competing studies
- || andecaliximab (GS-5745) / Gilead
Trial primary completion date, Combination therapy, Monotherapy, Metastases: Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Oct 18, 2016
P1, N=250, Recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Terminated | Trial primary completion date: Sep 2016 --> Feb 2016; Competing studies Trial primary completion date: Jan 2019 --> May 2019
- | napabucasin (BBI608) / Sumitomo Pharma
Phase classification, Combination therapy, Metastases: A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer (clinicaltrials.gov) - Oct 18, 2016
P1/2, N=609, Recruiting, Sponsor: Boston Biomedical, Inc
Trial primary completion date: Jan 2019 --> May 2019 Phase classification: P1 --> P1/2
- || 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date, Metastases: Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer (clinicaltrials.gov) - Oct 17, 2016
P2, N=56, Active, not recruiting, Sponsor: Richard Goldberg
Phase classification: P1 --> P1/2 Trial primary completion date: Sep 2016 --> Sep 2017
- || Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Trial primary completion date, Combination therapy, Metastases: GP28328: A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Oct 17, 2016
P1, N=235, Recruiting, Sponsor: Genentech, Inc.
Trial primary completion date: Sep 2016 --> Sep 2017 Trial primary completion date: Sep 2017 --> Dec 2018
- || napabucasin (BBI608) / Sumitomo Pharma
Trial primary completion date, Combination therapy, Metastases: A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer (clinicaltrials.gov) - Oct 17, 2016
P1, N=609, Recruiting, Sponsor: Boston Biomedical, Inc
Trial primary completion date: Sep 2017 --> Dec 2018 Trial primary completion date: Dec 2016 --> Dec 2019
- || Cyramza (ramucirumab) / Eli Lilly
New P3 trial, Metastases: ARMANI: Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers (clinicaltrials.gov) - Oct 16, 2016
P3, N=280, Not yet recruiting, Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
New P3 trial, Metastases: FDZL-FCI: FOLFIRI Versus Irinotecan as Second-line Treatment in Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - Oct 16, 2016
P3, N=164, Not yet recruiting, Sponsor: Fudan University
- Removab (catumaxomab) / NeoPharm, Trion Pharma
Trial primary completion date: Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas (clinicaltrials.gov) - Oct 14, 2016
P2, N=42, Active, not recruiting, Sponsor: AIO-Studien-gGmbH
Trial primary completion date: Dec 2016 --> Dec 2019 Trial primary completion date: Sep 2016 --> Dec 2016
- |||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open: CheckMate 649: Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (clinicaltrials.gov) - Oct 13, 2016
P3, N=870, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Sep 2016 --> Dec 2016 Not yet recruiting --> Recruiting
- Trial primary completion date: Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer (clinicaltrials.gov) - Oct 12, 2016
P3, N=2000, Active, not recruiting, Sponsor: Hellenic Oncology Research Group
Not yet recruiting --> Recruiting Trial primary completion date: Mar 2016 --> Nov 2016
- Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen
Trial primary completion date: BOS2: Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases (clinicaltrials.gov) - Oct 12, 2016
P2, N=44, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Trial primary completion date: Mar 2016 --> Nov 2016 Trial primary completion date: Dec 2015 --> Sep 2016
- || Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Trial primary completion date, Combination therapy: A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors (clinicaltrials.gov) - Oct 12, 2016
P1, N=60, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Dec 2015 --> Sep 2016 Trial primary completion date: Aug 2018 --> Nov 2018
- 5-fluorouracil / Generic mfg., cisplatin / Generic mfg., docetaxel / Generic mfg.
Biomarker, Trial primary completion date, Metastases: Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer. (clinicaltrials.gov) - Oct 11, 2016
P2, N=127, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: Aug 2018 --> Nov 2018 Trial primary completion date: Nov 2014 --> Nov 2017
- Rituxan (rituximab) / Roche
Trial primary completion date: S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma (clinicaltrials.gov) - Oct 11, 2016
P2, N=53, Terminated, Sponsor: Southwest Oncology Group
Trial primary completion date: Nov 2014 --> Nov 2017 Trial primary completion date: Sep 2016 --> Feb 2016
- |||||||||| pegilodecakin (LY3500518) / Eli Lilly
New P3 trial, Combination therapy, Metastases: Sequoia: Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Oct 5, 2016
P3, N=566, Not yet recruiting, Sponsor: ARMO BioSciences
- ||| sapitinib (AZD8931) / AstraZeneca
Phase classification, Enrollment change, Trial primary completion date, Combination therapy: PANTHER: Phase I/II Trial of Antagonism of HER in GI Cancer (clinicaltrials.gov) - Oct 4, 2016
P2, N=60, Recruiting, Sponsor: University College, London
Trial primary completion date: Sep 2016 --> Feb 2016 Phase classification: P1/2 --> P2 | N=24 --> 60 | Trial primary completion date: Jun 2016 --> Aug 2020
- Enrollment closed: Chemoradiation or Brachytherapy for Rectal Cancer (clinicaltrials.gov) - Oct 3, 2016
P2, N=138, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Phase classification: P1/2 --> P2 | N=24 --> 60 | Trial primary completion date: Jun 2016 --> Aug 2020 Recruiting --> Active, not recruiting
- | veliparib (ABT-888) / AbbVie, Keytruda (pembrolizumab) / Merck (MSD)
New P2 trial, PARP Biomarker, Metastases: NRG-GI002: Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer (clinicaltrials.gov) - Oct 3, 2016
P2, N=174, Not yet recruiting, Sponsor: National Cancer Institute (NCI)